- In April 2024, Generation Lab announced the upcoming official spring launch of what it calls the first clinically validated test that measures biological age and illness risk using epigenetic information. This development highlights the increasing trend of translating epigenetic research into consumer-facing diagnostic tools for preventative health
- In January 2024, AtlasXomics and EpiCypher collaborated to develop CUT&Tag products and diagnostic services for epidemiology applications. This partnership signifies a move towards expanding epigenetic diagnostics into public health and population-level studies
- In January 2024, Moonwalk Biosciences, a biotechnology startup, was launched after completing its seed and Series A financing rounds with USD 57 million to advance its epigenetic profiling and engineering technology platform. This significant funding indicates strong investor confidence in the future potential of epigenetic technologies for diagnostics and therapeutics
- In August 2023, Watchmaker Genomics Inc. teamed up with Exact Sciences Corp. to develop and commercialize a novel DNA methylation analysis technology called TET-assisted pyridine borane sequencing (TAPS). This partnership aims to improve cancer screening and diagnostic capabilities through advanced methylation analysis, crucial for early cancer detection and monitoring minimal residual disease
- In July 2023, FOXO Technologies Inc., a major player in epigenetic biomarker technology, introduced its cutting-edge Bioinformatics Services to leverage the full potential of epigenetic data. This service aims to help overcome challenges associated with data analysis and processing, indicating a growing emphasis on interpreting the vast amounts of epigenetic data generated
